Literature DB >> 35896903

Advanced Vesicular Systems for Antifungal Drug Delivery.

Shaimaa Mosallam1, Rofida Albash2, Manar Adel Abdelbari3.   

Abstract

Fungal infections are considered one of the most serious conditions as their occurrence has increased lately. Fungi like Candida, Fusarium, and Aspergillus species mostly affect immunocompromised patients as they are considered opportunistic pathogens. These infections can be superficial, cutaneous, subcutaneous, or systemic fungal infections that require specific treatment. There is a wide variety of antifungal drugs that can be used to cure fungal infections; however, most of them have many systemic side effects due to their physicochemical characteristics and high toxicity profile. Hence, the current review focuses on various advanced vesicular carriers with high biocompatibility that can encapsulate the antifungal drugs owing to increase their efficacy and limit the undesirable side effects. These advanced systems can manage stability, solubility, bioavailability, safety, and effectiveness issues present in conventional systems.
© 2022. The Author(s).

Entities:  

Keywords:  Advanced vesicular carriers; Antifungal drugs; Conventional systems; Fungal infections

Mesh:

Substances:

Year:  2022        PMID: 35896903     DOI: 10.1208/s12249-022-02357-y

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   4.026


  27 in total

Review 1.  A review on novel vesicular drug delivery: proniosomes.

Authors:  Venkata Ramesh Yasam; Satya Lavanya Jakki; Jawahar Natarajan; Gowthamarajan Kuppusamy
Journal:  Drug Deliv       Date:  2013-10-16       Impact factor: 6.419

Review 2.  New facets of antifungal therapy.

Authors:  Ya-Lin Chang; Shang-Jie Yu; Joseph Heitman; Melanie Wellington; Ying-Lien Chen
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

Review 3.  Toenail onychomycosis: an important global disease burden.

Authors:  J Thomas; G A Jacobson; C K Narkowicz; G M Peterson; H Burnet; C Sharpe
Journal:  J Clin Pharm Ther       Date:  2010-10       Impact factor: 2.512

Review 4.  Epidemiological trends in skin mycoses worldwide.

Authors:  Blanka Havlickova; Viktor A Czaika; Markus Friedrich
Journal:  Mycoses       Date:  2008-09       Impact factor: 4.377

5.  Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors.

Authors:  Markus Niewerth; Donika Kunze; Michael Seibold; Martin Schaller; Hans Christian Korting; Bernhard Hube
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 6.  Vulvovaginal candidosis.

Authors:  Jack D Sobel
Journal:  Lancet       Date:  2007-06-09       Impact factor: 79.321

Review 7.  Treatments of tinea pedis.

Authors:  Aditya K Gupta; Melody Chow; C Ralph Daniel; Raza Aly
Journal:  Dermatol Clin       Date:  2003-07       Impact factor: 3.478

8.  What are fungal infections?

Authors:  Ben E de Pauw
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-01-14       Impact factor: 2.576

Review 9.  Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials.

Authors:  Ibrahim M Abdulbaqi; Yusrida Darwis; Nurzalina Abdul Karim Khan; Reem Abou Assi; Arshad A Khan
Journal:  Int J Nanomedicine       Date:  2016-05-25

10.  Fungal infections in humans: the silent crisis.

Authors:  Katharina Kainz; Maria A Bauer; Frank Madeo; Didac Carmona-Gutierrez
Journal:  Microb Cell       Date:  2020-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.